Inhalatives Aviptadil zur Vorbeugung von COVID-19 assoziiertem akuten Atemwegssyndrom (ARDS)

Drug: Aviptadil 67?g;Drug: Placebo 0.9% NaCl solution

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- COVID-19 infection diagnosed

- Risk factors for the development of an ARDS according to an adapted EALI (early acute
lung injury score) = 2 Points (with at least one point from the EALI score)

EALI Score:

- 2-6l O2 supplementation to achieve a SaO2>90%: 1 point

- >6l O2 supplementation to achieve a SaO2>90%: 2 points

- Respiratory rate = 30/min: 1 point

- Immunosuppression: 1 Point

Modification (for adapting for risk factors for ARDS in SARS-CoV-2 affected patients

- Arterial hypertension: 1 point

- Diabetes: 1 point

- Fever > 39?C: 1 point

- Age > 18 years

- Ability to adequate compliance with the inhalation manoeuvre

- Ability to sign the informed consent

Exclusion Criteria:

- Known or highly suspected bacterial infection (antibiotic treatment to avoid bacterial
superinfection may be allowed)

- PCT = 1?g/l

- Mechanical ventilation

- Inability to conduct inhalation therapy

- Hemodynamic instability with requirement of vasopressor therapy

- Severe comorbidities interfering with the safe participation at the trial according to
the treating physician

- Pregnancy

- Systemic immunosuppression